The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global scar treatment market size reached US$ 13.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 21.2 Billion by 2027, exhibiting a growth rate (CAGR) of 9.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Scar treatment refers to the techniques and procedures employed for the remedy of acne, keloid, contracture, hypertrophic scars, etc. Scars are visible wound marks caused by surgeries, injuries or infections. The treatment and revision procedures are employed to minimize the appearance of these scars so that they look more consistent with the surrounding skin tone and texture. In order to speed up the healing process, various treatments are used, including over the counter (OTC) gels, ointments, creams, silicone sheets; surgeries for skin grafts, excisions or laser treatment; and collagen injections. In some cases, topical creams enriched with Vitamin E are also applied to diminish post-surgery scars.
The increasing prevalence of skin diseases, along with the rising consumer awareness regarding various scar treatment options, represent as the key factors driving the growth of the market. The growing aesthetic sense among the masses has led to the widespread adoption of skin treatment procedures. Furthermore, enhanced accessibility to dermatological facilities and the introduction of products containing both chemical and herbal ingredients are boosting the overall demand for the service. Dermatological clinics offer precise and latest technological procedures for cosmetic surgeries that provide effective results and cause minimal discomfort to the patient. Additionally, surgeries conducted using laser instruments are used for reducing the visibility of scars after critical injuries. These surgeries also speed up the healing process while ensuring a painless experience for the patient. Other factors, such as rising urbanization, inflating disposable incomes and the increase in affluent population, aggressive promotional activities by service providers and the introduction of organic and natural products, are projected to drive the market in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global scar treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product or treatment type, scar type and end-user.
Breakup by Product or Treatment Type:
Breakup by Scar Type:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Alliance Pharma PLC, AVITA Medical Ltd., Bausch Health Companies Inc., Cutera, Inc., Establishment Labs SA, GC Aesthetics PLC, Hologic Inc., Mölnlycke Health Care AB, Smith & Nephew PLC and Sonoma Pharmaceuticals Inc., etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product or Treatment Type, Scar Type, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Argentina, Colombia, Chile, Peru, Turkey, Saudi Arabia, Iran, United Arab Emirates|
|Companies Covered||Alliance Pharma PLC, AVITA Medical Ltd., Bausch Health Companies Inc., Cutera, Inc., Establishment Labs SA, GC Aesthetics PLC, Hologic Inc., Mölnlycke Health Care AB, Smith & Nephew PLC and Sonoma Pharmaceuticals Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global scar treatment market was valued at US$ 13.1 Billion in 2021.
We expect the global scar treatment market to exhibit a CAGR of 9.1% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cosmetic surgeries for scar treatment to reduce the risk of the coronavirus infection among the patients upon hospital visits and interaction with healthcare professionals or medical equipment.
The rising prevalence of various skin diseases, along with the increasing adoption of numerous laser instruments for reducing the visibility of scars after critical injuries, while ensuring a painless experience for the patient, is primarily driving the global scar treatment market.
Based on the product or treatment type, the global scar treatment market can be categorized topical products, laser treatment, surface treatment, and injectables. Currently, topical products hold the majority of the total market share.
Based on the scar type, the global scar treatment market has been segmented into atrophic scars, hypertrophic and keloid scars, contracture scars, and others. Among these, atrophic scars exhibit a clear dominance in the market.
Based on the end-user, the global scar treatment market can be bifurcated into hospitals, clinics, retail pharmacies, others. Currently, hospitals account for the largest market share.
On a regional level, the market has been classified into Asia Pacific, North America, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global scar treatment market include Alliance Pharma PLC, AVITA Medical Ltd., Bausch Health Companies Inc., Cutera, Inc., Establishment Labs SA, GC Aesthetics PLC, Hologic Inc., Mölnlycke Health Care AB, Smith & Nephew PLC, Sonoma Pharmaceuticals Inc., etc.
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at